Smith & Nephew to host Capital Markets Days in London and New York

SN

Smith & Nephew Plc (LON:SN, NYSE: SNN), the global medical technology company, has announced that it will host Capital Markets Days for institutional investors and financial analysts in London and New York on Monday 8 and Thursday 11 December 2025 respectively.

​The London event will introduce Smith+Nephew’s new strategy following the conclusion of the 12-Point Plan, including mid-term priorities and financial goals. This will be held at The Royal College of Surgeons from 1pm to 5pm GMT / 8am to 12pm EST on 8 December.

​The New York event will provide greater detail on Smith & Nephew’s innovative portfolio that will drive the next phase of growth, with insight from Smith+Nephew customers and Key Opinion Leaders. This event will be held at the New York Stock Exchange from 2pm to 6pm GMT / 9am to 1pm EST on 11 December.

​Both events will be led by Chief Executive Officer Deepak Nath, accompanied by Chief Financial Officer John Rogers and members of the Executive Committee. Further information will be provided in due course, and participants are encouraged to attend both events, either in person or virtually.

​In person attendance at these events requires pre-registration. Investors and analysts should register via Smith+Nephew’s website at https://www.smith-nephew.com/en/about-us/investors.

​The sessions will also be webcast and the presentations made available via the website.

Share on:

Latest Company News

Smith & Nephew CFO John Rogers to step down in September

Smith & Nephew has announced John Rogers will leave as chief financial officer, with Pierre Palassian appointed interim CFO until a successor is named.

Smith & Nephew and Imperial College London open surgical robotics innovation centre

Smith & Nephew and Imperial College London have launched a five-year partnership to accelerate research and innovation in robotic surgery.

Smith & Nephew maintains profit guidance as H1 trading margin improves

Smith & Nephew reported higher half-year revenue, operating profit and cash generation, while reducing full-year revenue guidance.

Smith & Nephew reports steady Q1 growth and confirms 2026 outlook

Underlying revenue grew 3.1% in Q1, supported by innovation and strong Sports Medicine performance. The company maintains its full-year targets and unveils a new $500m buyback program.

Smith & Nephew to host Surgeon Insights event in London

Smith & Nephew will host an investor event in London featuring US surgeons discussing innovation platforms across sports medicine, wound care, and orthopaedics, with presentations and Q&A sessions led by company leadership.

Smith & Nephew delivers higher profits and cash generation in 2025

Smith+Nephew reported full-year 2025 revenue of $6.16 billion, up 6.1% on a reported basis, with trading profit rising 15.5% and free cash flow increasing 52.5%.

    Search